A Phase 2 interventional study of TEV-48574 Dose Regimen A and TEV-48574 Dose Regiment B in Crohn Disease and Colitis, Ulcerative, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Active, not recruiting at 93 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Teva Branded Pharmaceutical Products R&D LLC (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Crohn Disease with a site in Poland — 34 open to participants now, 51 under way, 32 of them phase 3. Crohn Disease · Poland.
Among the 161 studies in Crohn Disease with a site in Poland, this one is the 69th largest by enrollment of the 152 interventional ones that give a count, is one of 10 that started in 2023, is one of 56 in phase 2, reaches primary completion later than 5 of the 50 other live ones, and was the 120th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →34 of the 161 studies in Crohn Disease with a site in Poland are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Poland, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Poland, United States, Belgium and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Poland, United States, Belgium and 7 more countries
Ages 18–80
Janssen Research & Development, LLC · Sites in Poland, United States, Austria and 14 more countries
Ages 18+
GLSMED Learning Health S.A. · Sites in Poland, Italy, Netherlands and 3 more countries
Ages 16–35 · Healthy volunteers
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 62 · Phase 3 89 · Phase 4 2
First in 2002; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 192 across the 152 interventional studies, 400 across the 9 observational. Of the 106 that completed or were terminated, 83 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
150 of 161 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D LLC, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D LLC is the lead sponsor of 24 studies on the registry; 7 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 8 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
17 of the studies in Crohn Disease with a site in Poland that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
Add all 17 to your calendar (.ics) → With an account.
Among the 161 studies in Crohn Disease with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).
Secondary objectives of the study are to:
The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NOTE- Additional criteria may apply, please contact the investigator for more information
Exclusion Criteria:
NOTE- Additional criteria apply, please contact the investigator for more information
Administered by subcutaneous infusion for participants with UC
Drug: TEV-48574 Dose Regimen A
Administered by subcutaneous infusion for participants with CD
Drug: TEV-48574 Dose Regimen A
Administered by subcutaneous infusion for participants with UC
Drug: TEV-48574 Dose Regiment B
Administered by subcutaneous infusion for participants with CD
Drug: TEV-48574 Dose Regiment B
Subcutaneous (sc) administration using a commercial sc infusion system
Also known as: duvakitug
Subcutaneous (sc) administration using a commercial sc infusion system
Also known as: duvakitug
Number of participants with moderate to severe ulcerative colitis (UC) who show clinical remission as defined by the Mayo score
Clinical remission based on modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of ≤2 points, which is defined by: * stool frequency subscore of 0 or 1, * rectal bleeding subscore of 0, and * endoscopic subscore of 0 or 1, where a score of 1 does not include "friability"
Time frame: Week 44
Number of participants with moderate to severe Crohn's disease (CD) who show an endoscopic response as defined by the Endoscopic Score for Crohn's Disease
Endoscopic response, defined as a decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) of at least 50% from DRF study baseline at week 44 in participants with CD
Time frame: Week 44
Number of participants with moderate to severe UC with a clinical response as defined by Mayo score
Clinical response at week 44, defined as a decrease from baseline in the modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of at least 2 points AND at least a 30% reduction from DRF baseline with either a decrease in rectal bleeding subscore of at least 1 or an absolute rectal bleeding subscore of less than or equal to 1
Time frame: Week 44
Number of participants with moderate to severe UC with Endoscopic improvement as defined by Mayo score
Endoscopic improvement defined as a Mayo endoscopic subscore of 0 or 1
Time frame: Week 44
Number of participants with moderate to severe UC in Endoscopic remission as defined by Mayo score
Endoscopic remission defined as a Mayo endoscopic subscore of 0
Time frame: Week 44
Number of participants with moderate to severe UC with Corticosteroid-free clinical remission based on the modified Mayo score
Defined by clinical remission and corticosteroid-free for ≥12 weeks preceding week 44
Time frame: Week 44
Number of participants with moderate to severe CD with a clinical response based on Crohn's Disease Activity Index
Clinical response defined as a ≥100-point decrease from DRF baseline Crohn's Disease Activity Index (CDAI) score
Time frame: Week 44
Number of participants with moderate to severe CD in clinical remission as defined by CDAI score
Clinical remission defined as a CDAI score less than 150
Time frame: Week 44
Number of participants with moderate to severe CD with Corticosteroid-free endoscopic response based on SES-CD
Defined by endoscopic response and corticosteroid-free for ≥12 weeks preceding week 44
Time frame: Week 44
Number of participants with moderate to severe CD with Corticosteroid-free clinical remission based on CDAI
Defined by a CDAI score of \<150 points and corticosteroid-free for ≥12 weeks preceding week 44
Time frame: Week 44
Number of participants who experience adverse events in the double-blind period
Adverse events can include any of the following clinically significant changes in clinical laboratory test results (serum chemistry, hematology, and urinalysis), vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate), 12-lead electrocardiogram (ECG), and injection site reactions.
Time frame: Up to Week 48
Number of participants who experience adverse events in the open-label (OL) period
Adverse events can include any of the following clinically significant changes in clinical laboratory test results (serum chemistry, hematology, and urinalysis), vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate), 12-lead electrocardiogram (ECG), and injection site reactions.
Time frame: Up to 5 years after start of OL period
Number of participants who stopped taking the investigational medicinal product (IMP) due to adverse events in the double-blind period
Time frame: Up to Week 48
Number of participants who stopped taking the investigational medicinal product (IMP) due to adverse events in the open-label (OL) period
Time frame: Up to 5 years after start of OL period
Number of participants with treatment emergent Anti-Drug Antibodies (ADA)
Time frame: Weeks 0, 4, 8, 16, 28, 44, and 48
Number of ADA positive participants with the presence of neutralizing ADA
Time frame: Weeks 0, 4, 8, 16, 28, 44, and 48
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
Ran from Jan 2023 to primary completion in Jan 2026, 35 months.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 35 months is close to that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2031 → Jan 2027, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duvakitug
Teva Branded Pharmaceutical Products R&D LLC →